Kandesar

Candesartan cilexetil, the active ingredient in Kandesar, is a Angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It is used to manage high blood pressure, support heart failure therapy, and protect kidney function in diabetic patients.

GNH USA supplies Kandesar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kandesar belongs to the Angiotensin II receptor blocker class and is employed in cardiovascular and renal disease management.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: improves symptoms and reduces hospitalisation by decreasing cardiac afterload. - Diabetic nephropathy: slows progression of kidney damage by lowering intraglomerular pressure.

Kandesar may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or general weakness. - Upper respiratory tract infection symptoms. - Nasal congestion or sinus discomfort.

Serious or Rare Side Effects: - Angioedema involving the face, lips, tongue or throat. - Significant hypotension leading to fainting. - Acute kidney injury or worsening renal function. - Hyperkalemia (elevated blood potassium). - Elevated liver enzymes indicating hepatic stress.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

- Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function assessment: check serum creatinine and eGFR periodically. - Electrolyte surveillance: monitor potassium levels, especially with concomitant potassium‑sparing agents. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Pregnancy: avoid use during pregnancy due to potential fetal toxicity. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Kandesar can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Combination with potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Co‑administration with ACE inhibitors: heightened risk of hypotension, hyperkalemia, and renal dysfunction.

Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate antihypertensive effect and impair renal function. - Lithium: candesartan can raise lithium levels, requiring serum monitoring. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase candesartan exposure. - Other antihypertensives: additive blood pressure‑lowering effect, necessitating dose adjustments.